These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2210980)

  • 41. The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration.
    Kasabian NG; Bauer SB; Dyro FM; Colodny AH; Mandell J; Retik AB
    Am J Dis Child; 1992 Jul; 146(7):840-3. PubMed ID: 1496955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
    Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
    Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topical oxybutynin chloride for relaxation of dysfunctional bladders.
    Brendler CB; Radebaugh LC; Mohler JL
    J Urol; 1989 Jun; 141(6):1350-2. PubMed ID: 2724432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
    O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
    J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
    Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
    Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oxybutynin and incontinence during grand mal seizures.
    Harari D; Malone-Lee JG
    Br J Urol; 1991 Dec; 68(6):658. PubMed ID: 1773301
    [No Abstract]   [Full Text] [Related]  

  • 47. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride.
    Madersbacher H; Jilg G
    Paraplegia; 1991 Feb; 29(2):84-90. PubMed ID: 2023781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxybutynin in the treatment of early detrusor instability after transurethral resection of the prostate.
    Iselin CE; Schmidlin F; Borst F; Rohner S; Graber P
    Br J Urol; 1997 Jun; 79(6):915-9. PubMed ID: 9202559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Idiopathic bladder hyperactivity treated with Ditropan (oxybutynin chloride).
    Nagy F; Hamvas A; Frang D
    Int Urol Nephrol; 1990; 22(6):519-24. PubMed ID: 2093692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Urodynamic variables cannot be used to classify the severity of detrusor instability.
    Wagg A; Bayliss M; Ingham NJ; Arnold K; Malone-Lee J
    Br J Urol; 1998 Oct; 82(4):499-502. PubMed ID: 9806177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Combination of oxybutynin chloride (Ditropan) with intermittent catheterization in the treatment of neurogenic bladder in childhood: results on continence].
    De Castro R; Casolari E; Ricci S
    Pediatr Med Chir; 1984; 6(6):795-803. PubMed ID: 6545593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of coexistent stress and urge urinary incontinence.
    Karram MM; Bhatia NN
    Obstet Gynecol; 1989 Jan; 73(1):4-7. PubMed ID: 2909042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial.
    Holmes DM; Montz FJ; Stanton SL
    Br J Obstet Gynaecol; 1989 May; 96(5):607-12. PubMed ID: 2667633
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Oxybutynin chloride in pediatrics: extenuating circumstances].
    Aubert D
    Arch Fr Pediatr; 1988 May; 45(5):375-6. PubMed ID: 3415420
    [No Abstract]   [Full Text] [Related]  

  • 55. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial.
    Ouslander JG; Schnelle JF; Uman G; Fingold S; Nigam JG; Tuico E; Jensen BB
    J Am Geriatr Soc; 1995 Jun; 43(6):610-7. PubMed ID: 7775717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients.
    Ouslander JG; Blaustein J; Connor A; Orzeck S; Yong CL
    J Urol; 1988 Jul; 140(1):47-50. PubMed ID: 3379694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis.
    Schulte-Baukloh H; Mürtz G; Henne T; Michael T; Miller K; Knispel HH
    BJU Int; 2006 Feb; 97(2):355-8. PubMed ID: 16430646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravesical oxybutynin in patients with posterior rhizotomies and sacral anterior root stimulators.
    Singh G; Thomas DG
    Neurourol Urodyn; 1995; 14(1):65-71. PubMed ID: 7742851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.